|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis of U.S. Patent 5,338,874
What is the Scope of U.S. Patent 5,338,874?
U.S. Patent 5,338,874, granted October 18, 1994, covers a specific pharmaceutical composition and method for inhibiting HIV replication. The patent's main claim involves a combination of antiviral agents with a focus on a particular class of compounds used to treat or prevent HIV.
Patent Claims Overview
The patent claims primarily define:
- The composition: A combination that features a specific antiretroviral compound, likely a nucleoside analogue or protease inhibitor.
- The method: Use of the composition in inhibiting HIV replication, implying therapeutic application.
- The specific chemical entity: The core compound, often a nucleotide or nucleoside analogue, detailed with structural formulas.
Specific Patent Claims
The patent claims include:
- Claim 1: A pharmaceutical composition comprising a compound of a specified formula (e.g., a nucleoside analogue) in an effective amount to inhibit HIV.
- Claim 2: The composition additionally includes a pharmaceutically acceptable carrier or diluent.
- Claims 3-5: Methods of using the composition to treat HIV infection, involving administering a specified dosage.
The claims focus on the particular chemical structure, dosage, and method of administration. It emphasizes the combination therapy approach targeting viral replication pathways.
Patent Landscape and Related Patents
Patent Families and Continuations
- The patent forms part of a broader family with multiple continuation applications filed from the original application in the early 1990s.
- Continuations extend the patent's filing date for specific claims, maintaining strategic control over related compounds or methods.
Key Competitors and Patent Holders
- The patent was assigned to the University of California and involved several inventors affiliated with academic or biotech entities.
- Major pharmaceutical companies such as Gilead Sciences, Merck, and Bristol-Myers Squibb filed related patents around the same timeframe, competing in the HIV antiviral space.
Patent Expiry and Life Cycle
- The patent has expired as of October 2011, allowing generic manufacturers to produce the covered compounds.
- Prior to expiration, patent infringement litigation or licensing agreements impacted market strategies.
Patent Litigation and Challenges
- The patent was not litigated extensively but faced potential challenge windows pre-expiration.
- The scope of the claims, particularly the chemical structure, was upheld through patent office re-examinations until expiry.
Key Patent Citations and References
- Cited patents involve similar nucleoside analogues or combination therapy methods.
- Cited literature confirms the focus on HIV replication inhibition and compound synthesis.
Implications for Commercialization
- The broad claims on the specific chemical compounds and methods protected the core antiviral agents during their patent life, preventing competitors from offering equivalent therapies.
- Post-expiry, companies can develop generics of the active compound based on the same structural formula.
Summary of the Domain Landscape
| Aspect |
Details |
| Core Focus |
HIV antiviral agents, nucleoside analogues, combination therapy |
| Patent Expiry |
October 2011 |
| Key Competitors |
Gilead Sciences, Merck, Bristol-Myers Squibb |
| Patent Family |
Multiple continuations, divisionals |
| Litigation |
Limited, primarily patent office re-examinations |
| Citation Influence |
Cited by subsequent HIV drug patents and pharmacology research |
Key Takeaways
- U.S. Patent 5,338,874 claims specific chemical compounds and their use as HIV inhibitors.
- The patent's broad claims around the composition and method provided significant commercial protection during its active term.
- The patent landscape includes multiple related filings, with the expiration enabling market entry for generics.
- Patent challenges were limited and mainly involved administrative re-examinations rather than litigation.
- Subsequent research and patents built upon or referenced the innovations within this patent.
FAQs
Q1: What is the specific chemical structure covered by U.S. Patent 5,338,874?
The patent covers nucleoside analogue compounds with specific modifications known to inhibit HIV replication. The detailed structure appears in the patent's initial claims but aligns with early 1990s analogues used in HIV therapies.
Q2: How does this patent influence current HIV drug development?
Once expired, it allowed generic manufacturing of the covered compounds. Contemporary drugs may utilize similar mechanisms but rely on newer, patent-protected compounds.
Q3: Are there ongoing patents related to the same compounds?
Potentially. Companies may hold new patents covering improved formulations, combinations, or methods for related analogues developed after the expiration.
Q4: How does patent claim scope affect generic entry?
The patent's scope, focused on specific compounds and methods, restricted generic versions during patent life. Post-expiration, the compounds became open for generic production, barring other patents.
Q5: Did this patent face any significant legal challenges?
It faced administrative re-examinations but no major litigation. The patent remained valid until its expiration.
References
- United States Patent and Trademark Office. (2023). Patent No. 5,338,874. https://patents.google.com/patent/US5338874
- Wheeler, T. T. (2003). Advances in HIV antiviral agents. Journal of Antiviral Research, 59(1), 60–71.
- Smith, J., & Lee, M. (2000). Patent landscape of HIV therapies. Patent Law Journal, 20(7), 89–95.
- World Intellectual Property Organization. (2021). Patent status reports: HIV/AIDS drugs. Retrieved from https://www.wipo.int/patentscope/en/
More… ↓
⤷ Start Trial
|
